Try our beta test site
3 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND MEDI-551 [TREATMENT]
Show Display Options
Rank Status Study
1 Completed A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: MEDI-551;   Drug: Rituximab;   Drug: Bendamustine
2 Completed Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas
Condition: Relapsed/Refractory Aggressive B-cell Lymphomas
Intervention: Drug: MEDI-551 and MEDI0680 (AMP-514)
3 Completed A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Drug: MEDI-551;   Drug: Rituximab;   Drug: ICE;   Drug: DHAP;   Procedure: Autologous Stem Cell Transplant (ASCT)

Study has passed its completion date and status has not been verified in more than two years.